Please sign in to follow a disease.
Diffuse large B-cell lymphoma germinal center B-cell type
MONDO:0850419A diffuse large B-cell lymphoma that is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.
2010 clinical trials for this condition and its sub-types, 13 tagged with Diffuse large B-cell lymphoma germinal center B-cell type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for blood cancer: targeted therapy combo shows promise in phase 2 trial
Disease control Recruiting nowThis study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma. About 594 adults who have no…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug cocktail ViPOR targets tough lymphomas in phase II trial
Disease control Recruiting nowThis phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug tegavivint takes on tough lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …
Phase 1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Phase 1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough blood cancers: experimental drug AC676 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like leukemia or lymphoma) that returned or didn't respond to prior treatments. The main goals are to find a safe dose and understand side effects. Researchers will also check how …
Phase 1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC